VisMederi will be present also this year at the Annual Meeting of ADITEC project to be held in Brussels on November 7 to 9 in 2016.
ADITEC (Advanced Immunization Technologies) is a five-year project that began in 2011 thanks to the collaboration of scientists from 13 countries and 42 research partners whose goal is the identification and development of innovative immunization technologies for the future generation of human vaccines.
VisMederi has used the knowledge and skills of its researchers by joining forces with the most competitive and technologically advanced European and American research groups since 2012, to ensure the sustainability and success of this enterprise.
The main contribution of VisMederi in the year 2016 has been the investigation of the humoral immune response to the flu vaccine through the HAI (Haemagglutination Inhibition) serological test carried out on 1172 serum samples from 586 subjects, which were administered the flu vaccine in autumn 2015. The test was performed according to the procedures of Good Clinical Laboratory Practices in VisMederi. The activities were conducted in close collaboration with DeCODE genetics and the data obtained will be able to reveal the correlation between the humoral response and sequence variants in the genome.
Professor Emanuele Montomoli, VisMederi’s CSO, will also attend the “Vaccine Research and Development in Europe” event to be held at the European Parliament on the occasion of the aforementioned meeting dealing with vaccines as a strategic sector for Europe, new opportunities for research and with the success achieved in recent years by the ADITEC project.